Objectives

White blood cells (WBCs) are immune cells that fight infections and cancers. However, many cancers and their treatment with chemotherapy negatively affect the WBCs count. For oncologists and physicians, it is important to know how much the WBCs count is affected to optimize drug administration. The data of breast cancer patients were included in this study because the largest number of cancer patients were suffering from breast cancer in the under-study hospital. This study presents a computational and mathematical approach to measure the effect on the WBCs count of breast cancer patients treated with chemotherapy with two anticancer drug combinations: docetaxel with cyclophosphamide (TC) and doxorubicin with cyclophosphamide (AC).

Methods

Between July 2016 and October 2021, to breast cancer patients, 4 cycles of chemotherapy (one cycle of 21 days) were administered intravenously using TC (75 mg/m² + 600 mg/m²). Similarly, varying in cases, intravenous AC (60 mg/m² + 600 mg/m²) was administered in each of the 4 cycles. The WBCs counts of the subjects affected by both TC and AC combinations were observed for comparison. An equation was derived to calculate the effect of TC and AC on WBCs count (eWBCc). The eWBCc of 171 patients who received TC and 154 patients who received AC were calculated by implantation of the derived equation using Python 3.8.

Results

Comparing the results of 171 patients, it is observed that, TC affected WBC count of a patient at lowest level by 12.29%, at maximum level by 69.64%, and on average by 34.13%. Whereas, comparing the results of 154 patients, AC affected WBC count of a patient at lowest level by 19%, at maximum level by 65.03%, and on average, by 44.36%. A paired t-test was used to analyze the statistical differences between the eWBCc of both TC and AC cohorts. This test indicates a statistically significant difference between the eWBCc by TC and AC, as evidenced by the P-value of 0.000, which is less than the chosen significance level (alpha) of 0.05.

Conclusion

We conclude that TC remains less toxic than AC in affecting white blood cells count of the studied patients.

中文翻译：

---

量化抗癌药物对癌症患者白细胞计数的毒性：数学和计算方法

目标

白细胞 (WBC) 是抵抗感染和癌症的免疫细胞。然而，许多癌症及其化疗会对白细胞计数产生负面影响。对于肿瘤学家和医生来说，了解白细胞计数受到的影响对于优化药物管理非常重要。本研究纳入了乳腺癌患者的数据，因为研究医院中患乳腺癌的癌症患者数量最多。本研究提出了一种计算和数学方法来测量接受两种抗癌药物组合化疗的乳腺癌患者白细胞计数的影响：多西紫杉醇与环磷酰胺（TC）和阿霉素与环磷酰胺（AC）。

方法

^{2016年7月至2021年10月期间，乳腺癌患者使用TC（75 mg/m 2}  + 600 mg/m ²）静脉注射化疗4个周期（1个周期21天）。类似地，根据情况不同，在4个周期的每一个周期中施用静脉内AC(60mg/m ²  +600mg/m ^{2 )。}观察受 TC 和 AC 组合影响的受试者的白细胞计数以进行比较。推导了一个方程来计算 TC 和 AC 对白细胞计数 (eWBCc) 的影响。通过使用 Python 3.8 植入导出的方程，计算了 171 名接受 TC 的患者和 154 名接受 AC 的患者的 eWBCc。

结果

对比171例患者的结果发现，TC对患者白细胞计数的影响最低为12.29%，最高为69.64%，平均为34.13%。而比较154名患者的结果，AC对患者白细胞计数的影响最低水平为19%，最高水平为65.03%，平均为44.36%。使用配对t检验来分析 TC 和 AC 队列的 eWBCc 之间的统计差异。该检验表明 TC 和 AC 的 eWBCc 之间存在统计显着性差异，P 值为 0.000，小于所选的显着性水平 (alpha) 0.05。

结论

我们得出的结论是，在影响所研究患者的白细胞计数方面，TC 的毒性仍低于 AC。